Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

Core Points - VolitionRx Limited and its subsidiary donated the Nu.Q® Vet Cancer Test to support crisis response dogs at the HOPE AACR Annual Conference, emphasizing their commitment to corporate social responsibility [1][3][4] - The Nu.Q® Vet Cancer Test is designed for preventive check-ups in older dogs and high-risk breeds, aiming to improve early cancer detection and enhance the quality of life for both dogs and their owners [2][9] - The test is non-invasive, cost-effective, and has been sold in over 20 countries, with more than 100,000 tests sold in 2024 [9][10] Company Overview - Volition is a multinational epigenetics company focused on advancing the science of epigenetics to improve outcomes for people and animals through early disease detection [10][11] - The company is developing and commercializing blood tests for diagnosing and monitoring various diseases, including cancers and conditions associated with NETosis [11][12] - Volition's research and development activities are based in Belgium, with additional offices in the U.S. and London [12]